Q3 Asset Management Summit Therapeutics Inc. Transaction History
Q3 Asset Management
- $404 Million
- Q3 2024
A detailed history of Q3 Asset Management transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Q3 Asset Management holds 16,473 shares of SMMT stock, worth $294,043. This represents 0.09% of its overall portfolio holdings.
Number of Shares
16,473Holding current value
$294,043% of portfolio
0.09%Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
192Shares Held
75.8MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$436 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$195 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$141 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$97.1 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$61.9 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.59B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...